Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment.

Non-small cell lung cancer, ovarian cancer, and pancreatic cancer all present with high morbidity and mortality. Systemic chemotherapies have historically been the cornerstone of standard of care (SOC) regimens for many cancers, but are associated with systemic toxicity. Multimodal treatment combinations can help improve patient outcomes; however, implementation is limited by additive toxicities and potential drug-drug interactions. As such, there is a high unmet need to develop additional therapies to enhance the efficacy of SOC treatments without increasing toxicity. Tumor Treating Fields (TTFields) are electric fields that exert physical forces to disrupt cellular processes critical for cancer cell viability and tumor progression. The therapy is locoregional and is delivered noninvasively to the tumor site via a portable medical device that consists of field generator and arrays that are placed on the patient's skin. As a noninvasive treatment modality, TTFields therapy-related adverse events mainly consist of localized skin reactions, which are manageable with effective acute and prophylactic treatments. TTFields selectively target cancer cells through a multi-mechanistic approach without affecting healthy cells and tissues. Therefore, the application of TTFields therapy concomitant with other cancer treatments may lead to enhanced efficacy, with low risk of further systemic toxicity. In this review, we explore TTFields therapy concomitant with taxanes in both preclinical and clinical settings. The summarized data suggest that TTFields therapy concomitant with taxanes may be beneficial in the treatment of certain cancers.

Déclaration de conflit d'intérêts

I.V. reports that consulting fees were received from Agenus, Akesobio, AstraZeneca, Bristol Myers Squibb, Deciphera Pharmaceuticals, Eisai, Elevar Therapeutics, F. Hoffmann-La Roche, Genmab, GSK, Immunogen, Jazzpharma, Karyopharm, Mersana, MSD, Novocure, Novartis, Oncoinvent, OncXerna, Sanofi, Seagen, Sotio, Verastem Oncology, and Zentalis; contracted research was via KULeuven from Oncoinvent AS; corporate sponsored research was from Amgen, Roche; accommodation and travel expenses were from Karyopharm, Genmab, Novocure. T.M. reports consulting or advisory roles with Ability Pharma, AstraZeneca, Basilea, Baxter, BioLineRX, Celgene, Eisai, Genzyme, Incyte, Ipsen, Lilly, MSD, Novocure, QED Therapeutics, Roche, Sanofi/Aventis, SERVIER, and Zymeworks; and travel, accommodation, and expenses were from Celgene, H3 Biomedicine, Incyte, Merck, Sanofi, and SERVIER. F.R.H. reports honoraria for participation in scientific advisory boards for Amgen, Bristol-Myers Squibb, AstraZeneca/Daiichi, Regeneron/Sanofi, Novartis, Blueprint Medicine, G1 Therapeutics, Novocure, NextCure, Nectin Therapeutics, OncoCyte, and Genentech; C.H. reports that research grants; travel, accommodation, and expenses; and speaking honoraria were from Novocure. D.S.M. reports honoraria for a consulting/advisory role were from Eisai, AstraZeneca, Karyopharm Therapeutics, Incyte, MSD, Asymmetric Therapeutics, LLC, Boston Biomedical Research Institute, Tarveda Therapeutics, Myriad Genetic Laboratories Inc, GlaxoSmithKline LLC, AbbVie, Incyte, EMD Serono, Seagen, Clinical Education Alliance, Eisai Europe Limited, GlaxoSmithKline, iTeos Belgium SA, Novocure, Novartis, and Immunogen Agenus; honoraria for speaking were from Clovis Oncology, Genentech; funding for research was from EMD Serono Research & Development and Leap Therapeutics.